Navigation Links
Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
Date:3/26/2009

COSTA MESA, Calif., March 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has added clinical trial sites in Israel for the planned Phase II dose escalation study of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier. The Israeli sites are in addition to those previously planned for Switzerland.

"Israeli physicians are excited to be able to participate in this study, especially as it relates to TBI as a result of blast injury," said Chris J. Stern, company chairman and CEO. "Unfortunately, they have had to deal with blast victims for some time, both military and civilian. They see this as something that can help them improve outcomes for the victims they treat. They also have one of the best medical systems in the world and are especially skilled in treating TBI. So the data they collect should be absolutely first rate," said Stern.

Plans call for up to six treatment sites in Israel, the same number as in Switzerland. They will also use the same clinical protocol. All trials will be supervised by the Israeli affiliate of PFC Pharma Focus AG, a Swiss-based contract research organization. The company expects to begin the clinical trials in the second quarter.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in m
'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Expands Board of Directors
2. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
3. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
4. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
5. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
8. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
11. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
(Date:10/20/2014)... 20, 2014 PureTech , a science ... healthcare problems, announced today the closing of a ... from Invesco Perpetual, a $120 Billion group of ... PureTech,s existing pipeline forward and to advance new ... scientific creativity to really go for the big ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Local veterinary ... in an investigational study of donor stem cells for ... stem cell therapy and has performed clinical stem cell ... study is to determine if a single injection of ... joints can help reduce pain and inflammation in the ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... of heterologous proteins , Carsten-Peter Carstens ... , Codon bias is a significant obstacle for ... In GC-rich genomes, such as mammals,rare arginine codons ... most frequently,affect bacterial gene expression. For such situations, ...
... TaqPlus Precision PCR system, developed for,highfidelity PCR , ... Bai * Daniel McMullan,* Barbara McGowan * Holly Hogrefe ... addition of the TaqPlus Precision PCR system,* to an ... system,consists of a novel mixture of Taq2000 and Pfu ...
... , High-level expression of difficult heterologous proteins ... has created variants of the Epicurian Coli ... of strains, which contain extra copies of the E. ... for a high-level,expression of proteins that are difficult to ...
Cached Biology Technology:New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 2New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 3New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 4High-Fidelity PCR with a Novel Polymerase Mixture 2High-Fidelity PCR with a Novel Polymerase Mixture 3High-Fidelity PCR with a Novel Polymerase Mixture 4High-Fidelity PCR with a Novel Polymerase Mixture 5High-Fidelity PCR with a Novel Polymerase Mixture 6High-Fidelity PCR with a Novel Polymerase Mixture 7High-Fidelity PCR with a Novel Polymerase Mixture 8High-Fidelity PCR with a Novel Polymerase Mixture 9High-Fidelity PCR with a Novel Polymerase Mixture 10High-Fidelity PCR with a Novel Polymerase Mixture 11Codon Bias-Adjusted BL21 Derivatives for Protein Expression 2Codon Bias-Adjusted BL21 Derivatives for Protein Expression 3Codon Bias-Adjusted BL21 Derivatives for Protein Expression 4Codon Bias-Adjusted BL21 Derivatives for Protein Expression 5Codon Bias-Adjusted BL21 Derivatives for Protein Expression 6Codon Bias-Adjusted BL21 Derivatives for Protein Expression 7
(Date:10/22/2014)... identity analyst firm Acuity Market Intelligence forecasts that in ... have a chip-based National eID card, including near-complete regional ... Asia , with its vast population, is expected ... of all National eID cards issued between 2014 and ... National eID Industry Report: 2014 Edition" — projects ...
(Date:10/19/2014)... over the last 30 years contributed only marginally ... that time, according to a new study published ... "Energy access is fundamental to development: it brings ... communication, and health," says IIASA researcher Shonali Pachauri, ... access is widely agreed to be an important ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... from a blue whale to a human being, poses ... cells in its body will die without reproducing; only ... next generation. How could the extreme degree of ... all creatures unicellular individualists determined to pass on their ...
... Shenzhen, China BGI, the world,s largest ... its first cloud computing terminal server, in China ... for users without bioinformatics background and it allows ... in their own laboratories with the advantages of ...
... NL -- Parkinson,s disease is marked by the abnormal ... neurons in the substantia nigra region of the brain. ... as NACP-Rep1 has been implicated as a risk factor ... different variants of NACP-Rep1 and its interaction with the ...
Cached Biology News:Close family ties keep microbial cheaters in check, study finds 2Close family ties keep microbial cheaters in check, study finds 3Close family ties keep microbial cheaters in check, study finds 4Close family ties keep microbial cheaters in check, study finds 5BGI-BOX terminal server debut operation in China Agricultural University 2Genetic factors can predict the progression of Parkinson's disease 2
Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: